Akebia Therapeutics Inc
AKBA3.720USD
0.000
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
973.32MCap. mercado
PérdidaP/E TTM
Más Datos de Akebia Therapeutics Inc Compañía
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Información de la empresa
Símbolo de cotizaciónAKBA
Nombre de la empresaAkebia Therapeutics Inc
Fecha de salida a bolsaMar 20, 2014
Director ejecutivoMr. John P. Butler
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 20
Dirección245 First Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Teléfono16178712098
Sitio Webhttps://akebia.com/
Símbolo de cotizaciónAKBA
Fecha de salida a bolsaMar 20, 2014
Director ejecutivoMr. John P. Butler
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 31 de jul
Actualizado: jue., 31 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
13.32%
Investment Advisor/Hedge Fund
10.58%
Hedge Fund
9.31%
Individual Investor
3.61%
Research Firm
2.48%
Private Equity
2.19%
Bank and Trust
0.14%
Pension Fund
0.04%
Insurance Company
0.03%
Other
58.30%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
281
109.59M
41.73%
+26.45M
2025Q1
280
111.54M
42.50%
+30.68M
2024Q4
258
78.54M
36.08%
+7.41M
2024Q3
257
64.16M
30.51%
-2.18M
2024Q2
248
61.31M
29.27%
-7.52M
2024Q1
290
61.37M
29.36%
-12.30M
2023Q4
289
58.79M
31.24%
-20.79M
2023Q3
300
57.28M
30.45%
-25.18M
2023Q2
308
56.18M
30.22%
-26.52M
2023Q1
315
56.14M
30.23%
-26.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
13.97M
5.32%
+133.23K
+0.96%
Mar 31, 2025
The Vanguard Group, Inc.
12.69M
4.83%
+1.80M
+16.55%
Mar 31, 2025
State Street Global Advisors (US)
6.81M
2.59%
+501.11K
+7.95%
Mar 31, 2025
Alerce Investment Management, L.P.
5.75M
2.19%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.19%
+5.75M
--
Dec 31, 2024
Geode Capital Management, L.L.C.
5.03M
1.92%
+235.65K
+4.91%
Mar 31, 2025
Great Point Partners, LLC
4.97M
1.89%
+4.97M
--
Mar 31, 2025
Renaissance Technologies LLC
4.01M
1.53%
+182.30K
+4.77%
Mar 31, 2025
Citadel Advisors LLC
3.65M
1.39%
+2.26M
+163.86%
Mar 31, 2025
Franklin Advisers, Inc.
2.67M
1.02%
+2.50M
+1495.36%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ALPS Medical Breakthroughs ETF
0.65%
Invesco NASDAQ Future Gen 200 ETF
0.54%
Federated Hermes MDT Small Cap Core ETF
0.27%
SPDR S&P Biotech ETF
0.23%
iShares Micro-Cap ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.13%
iShares Russell 2000 Value ETF
0.06%
Global X Russell 2000 ETF
0.04%
Ver más
ALPS Medical Breakthroughs ETF
Proporción0.65%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.54%
Federated Hermes MDT Small Cap Core ETF
Proporción0.27%
SPDR S&P Biotech ETF
Proporción0.23%
iShares Micro-Cap ETF
Proporción0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.13%
Fidelity Enhanced Small Cap ETF
Proporción0.13%
iShares Russell 2000 Value ETF
Proporción0.06%
Global X Russell 2000 ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
